SRR2016973
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.450
- OXIDATIVE_PHOSPHORYLATION+0.420
- IL6_JAK_STAT3_SIGNALING+0.390
- MTORC1_SIGNALING+0.320
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.320
- P53_PATHWAY+0.310
- PROTEIN_SECRETION+0.310
- FATTY_ACID_METABOLISM+0.300
- INFLAMMATORY_RESPONSE+0.280
- CHOLESTEROL_HOMEOSTASIS+0.250
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- HEDGEHOG_SIGNALING-0.340
- UV_RESPONSE_DN-0.340
- WNT_BETA_CATENIN_SIGNALING-0.270
- TGF_BETA_SIGNALING-0.260
- MITOTIC_SPINDLE-0.210
- ANGIOGENESIS-0.190
- MYOGENESIS-0.180
- NOTCH_SIGNALING-0.150
- PANCREAS_BETA_CELLS-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | bc895549-854b-484f-8a6d-9e5152829bcb | — | — | 0.837 |
| 2 | TCGA-39-5011-01A-01R-1443-07 | — | cohortA1 | 0.816 |
| 3 | a8e85cdd-3770-40a0-837e-6962ec12fcf0 | — | — | 0.812 |
| 4 | SRR12696807 | — | — | 0.797 |
| 5 | TCGA-BA-5152-01A-02R-1873-07 | — | — | 0.794 |
| 6 | 4769f22f-eeaf-4108-9555-55cc5d6ae27b | — | — | 0.788 |
| 7 | a3b44031-71ef-476f-a8bd-3694226ce026 | — | — | 0.785 |
| 8 | TCGA-49-4488-01A-01R-1755-07 | — | cohortA1 | 0.778 |
| 9 | db087000-74fa-4044-812f-01842b99f448 | — | — | 0.777 |
| 10 | SRR23036888 | — | — | 0.775 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.450 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.390 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.320 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.310 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.310 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.250 | Temsirolimus | — uncovered |
| PEROXISOME | 0.240 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.240 | Inavolisib | — uncovered |
| COMPLEMENT | 0.230 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.230 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.220 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.190 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.170 | Inavolisib | — uncovered |